Taiwan's newborn screening policy is expanding once again. The Ministry of Health and Welfare announced that starting in July this year, the current 21 newborn congenital metabolic disorder screening items will shift from partial subsidies to fully government-funded coverage, meaning parents will no longer need to pay any additional fees. At the same time, screening for Spinal Muscular Atrophy (SMA) will be added, officially expanding the publicly funded newborn screening program to 22 items.
Taiwan's newborn screening scale ranks among Asia's leaders
Only a limited number of countries worldwide are truly able to implement large-scale newborn disease screening programs. In Malaysia, for example, publicly funded screening covers only about one to two items. By comparison, Taiwan has gradually expanded its newborn screening items from 11 in 2019 to 21, and now to 22 with the addition of SMA, placing the country among the leading systems in Asia.
Previously, although the government provided subsidies, parents still had to cover part of the cost themselves. Beginning in July, the program will become fully publicly funded, allowing all newborns to receive all 22 screening items without paying any additional fees. The policy is expected to reduce financial pressure on families while also improving screening accessibility and participation rates.
SMA has been added to the screening program, marking a move toward early intervention for rare disease treatment.（Photo／provided by Mama & Baby）
SMA added to screening, rare disease treatment moves toward early intervention
One of the biggest highlights of the new policy is the official inclusion of SMA in the publicly funded newborn screening program. SMA is a rare inherited neuromuscular disease in which motor neurons gradually deteriorate, leading to muscle weakness and atrophy throughout the body. In severe cases, it can even affect breathing function and was once considered one of the rare diseases with high infant mortality rates.
In recent years, SMA treatment has seen major breakthroughs with the development of gene therapy, oral medications, and spinal injection treatments. Taiwan's National Health Insurance system currently covers several expensive SMA medications, including a gene therapy treatment costing as much as NT$49 million for a single dose, regarded as an important milestone in Taiwan's rare disease healthcare system.
In addition to newborn screening, regular vaccinations for babies are also very important.（Photo／provided by Mama & Baby）
For SMA, “the earlier it is detected and treated, the better the outcome.” If genetic defects can be identified during the newborn stage through screening and treatment begins promptly, a child's future development and quality of life may be significantly improved. For some diseases, the golden treatment window can be extremely short, and missing it may result in far greater costs later on.
In addition to newborn screening, parents should also not overlook the importance of routine vaccinations for babies. Completing vaccinations according to the recommended schedule not only helps build immunity but also reduces the risk of severe infections, providing additional protection for a child's healthy growth.
This article is used with authorization from Mama & Baby.
